News
FATE
3.760
-3.09%
-0.120
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
NASDAQ · 16h ago
Weekly Report: what happened at FATE last week (0902-0906)?
Weekly Report · 3d ago
Weekly Report: what happened at FATE last week (0826-0830)?
Weekly Report · 09/02 11:30
Fate Therapeutics Strengthens Legal Safeguards for Leadership
TipRanks · 08/30 20:49
Weekly Report: what happened at FATE last week (0819-0823)?
Weekly Report · 08/26 11:28
Fate Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 08/22 11:44
HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target
Benzinga · 08/22 11:34
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)
TipRanks · 08/22 10:20
Fate Therapeutics: Hold Rating Amid Financial Stability and Upcoming Milestones
TipRanks · 08/22 10:20
Fate Therapeutics’ Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522
TipRanks · 08/20 06:45
Weekly Report: what happened at FATE last week (0812-0816)?
Weekly Report · 08/19 11:14
Fate Therapeutics (FATE) Gets a Hold from Stifel Nicolaus
TipRanks · 08/19 02:15
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy
NASDAQ · 08/16 16:00
Fate Therapeutics: Hold Rating Amidst Steady Q2 Financials and Clinical Progress
TipRanks · 08/16 06:31
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
NASDAQ · 08/14 14:07
Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
TipRanks · 08/14 12:16
Fate Therapeutics: Market Perform Rating Amidst Anticipated Data and Pipeline Progress
TipRanks · 08/14 11:27
Piper Sandler Keeps Their Buy Rating on Fate Therapeutics (FATE)
TipRanks · 08/14 11:07
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Achieve Life Sciences (ACHV) and Kezar Life Sciences (KZR)
TipRanks · 08/14 10:50
Fate Therapeutics: A Cautious Hold Amidst Early Clinical Developments
TipRanks · 08/14 10:47
More
Webull provides a variety of real-time FATE stock news. You can receive the latest news about Fate Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.